<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094285</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-070119</org_study_id>
    <nct_id>NCT04094285</nct_id>
  </id_info>
  <brief_title>The Effect of Hyperoxia and Hypoxia on Fluorescence Lifetime Imaging Ophthalmoscopy in Healthy Subjects- a Randomized, Double Blind, Crossover Study</brief_title>
  <official_title>The Effect of Hyperoxia and Hypoxia on Fluorescence Lifetime Imaging Ophthalmoscopy in Healthy Subjects- a Randomized, Double Blind, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to investigate whether FLIO can also detect shorttime changes in&#xD;
      retinal metabolism induced by hyperoxia and hypoxia. For this purpose, 48 healthy subjects&#xD;
      will be included in the present study and changes in FLIO will be assessed during breathing&#xD;
      of 100% oxygen to induce hyperoxia as well as during breathing of 12% oxygen in nitrogen to&#xD;
      induce hypoxia. Since stimulation with flickering light also induces a higher metabolic&#xD;
      demand in the retina (functional hyperemia), thisprovocation test will also applied during&#xD;
      breathing of the different gas mixtures and compared to baseline. To gain information about&#xD;
      retinal blood flow, optical coherence tomography angiography (OCT-A) will be performed. The&#xD;
      results of the present study can help to gain more insight into the physiology of the retinal&#xD;
      metabolism and might give grounds to establish new biomarkers in future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in FLIO induced by hyperoxia</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in FLIO induced by hypoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FLIO induced by flicker stimulation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by hyperoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by hypoxia</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in OCT-A induced by flicker stimulation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal vessel diameter</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peripheral oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood gas parameters (pH, pCO2, PO2 and SaO2)</measure>
    <time_frame>15 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>To Investigate the Effect of 100% Oxygen Breathing on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAUERSTOFF</intervention_name>
    <description>SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria&#xD;
Dose:&#xD;
min. 95.5%, breathing for 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STICKSTOFF</intervention_name>
    <description>STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria&#xD;
Dose:&#xD;
88% with 12% oxygen, breathing for 30 minutes</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged between 18 and 35 years&#xD;
&#xD;
               -  Normal ophthalmic findings&#xD;
&#xD;
               -  Ametropia â‰¤ 6 diopters&#xD;
&#xD;
               -  Normal findings in the medical history and physical examination including ECG&#xD;
                  unless the investigator considers an abnormality to be clinically irrelevant&#xD;
&#xD;
               -  Nonsmokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Regular use of medication, abuse of alcoholic beverages or drugs&#xD;
&#xD;
          -  Participation in a clinical trial in the 3 weeks preceding the study&#xD;
&#xD;
          -  Treatment in the previous 3 weeks with any drug (except contraceptives)&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Women of childbearing potential (neither menopausal, nor hysterectomized, nor&#xD;
             sterilized) not using effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna, Austria</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhofer, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD. Dr. med. univ.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

